Soleno Therapeutics Inc

-0.02 (-1.72%)
Products, Regulatory

Soleno Therapeutics Provides Regulatory Update On Dccr For The Treatment Of Prader-Willi Syndrome

Published: 07/06/2021 12:41 GMT
Soleno Therapeutics Inc (SLNO) - Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-willi Syndrome.
Soleno Therapeutics - FDA Continued to Assert That Based on Data They Have Seen to Date, Additional Clinical Trial is Necessary for Submission of NDA.
Soleno Therapeutics Inc - Intend to Submit Additional Data From Destiny Pws and C602 Extension Study to Agency Before End of Q3.
Soleno Therapeutics- FDA Agreed to Review Additional Data to Determine If Totality of Data Generated to Date Enough to Support Potential NDA Submission.